| HS Code | 228640 |
| Generic Name | Metformin |
| Brand Names | Glucophage, Glumetza, Fortamet, Riomet |
| Drug Class | Biguanide, Antidiabetic agent |
| Indication | Type 2 diabetes mellitus |
| Dosage Form | Tablet, Extended-release tablet, Oral solution |
| Route Of Administration | Oral |
| Mechanism Of Action | Decreases hepatic glucose production and increases insulin sensitivity |
| Usual Adult Dose | 500 mg to 2,000 mg per day in divided doses |
| Common Side Effects | Gastrointestinal upset, diarrhea, nausea, abdominal pain |
| Contraindications | Renal impairment, metabolic acidosis, hypersensitivity |
As an accredited Metformin factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | White plastic bottle labeled "Metformin 500 mg," containing 100 tablets, featuring tamper-evident seal and dosage instructions on the label. |
| Shipping | Metformin is shipped in tightly sealed, clearly labeled containers to prevent contamination and moisture exposure. It is transported in compliance with international chemical safety regulations, typically at controlled room temperature. Proper protective measures and documentation accompany the shipment to ensure safe handling, storage, and delivery to authorized facilities or recipients. |
| Storage | Metformin should be stored at room temperature, typically between 20°C to 25°C (68°F to 77°F), away from excessive heat, moisture, and light. The medication should be kept in its original, tightly-closed container and out of reach of children and pets. Avoid storing Metformin in the bathroom or near sinks to prevent exposure to humidity. Dispose of expired tablets properly. |
Competitive Metformin prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Metformin hydrochloride belongs to a fundamental group of pharmaceutical ingredients that drive advancements in diabetes treatment across global markets. From my vantage point as a manufacturer in the chemical and pharmaceutical sector, every batch that leaves our facility mirrors relentless attention to quality controls, consistency measures, and strict adherence to pharmacopeial standards.
Metformin started gaining traction in both research and clinical environments many decades ago. On the manufacturing floor, we see it as more than just another tablet ingredient. It represents a direct commitment to supporting patients with type 2 diabetes, and its role in managing blood sugar levels has set the tone for how modern bulk pharmaceutical ingredients should be produced and evaluated. In the global market, we've watched demand grow in tandem with increasing diabetes prevalence, keeping every part of our production chain alert and honest.
Production lines in our facility run with models specifically tailored for bulk Metformin hydrochloride, most commonly synthesizing product with particle sizes that optimize tablet formulation and stability during storage. The standard model we supply meets pharmacopoeia specifications such as those outlined in the United States Pharmacopeia (USP), European Pharmacopeia (EP), and Chinese Pharmacopeia (ChP). Our typical Metformin grade comes in white to off-white crystalline powder form, with an emphasis on particle size distribution that supports direct compression, wet granulation, or capsule filling. Each lot achieves an assay not less than 97% and not more than 103% on a dried basis, aligning with pharmacopeial monographs.
Stringent controls on residual solvents and impurity profiles help ensure a safe active ingredient. By maintaining levels of known and unknown impurities below thresholds published in global regulatory guidelines, we guarantee compliance during drug registration both in established and emerging markets. Each sample batch goes through multiple checks—starting from raw material sourcing to in-process verification and final packaging under GMP conditions—so downstream manufacturers, such as finished dosage formulators, never question the material's origins or reliability.
Every kilogram of Metformin we produce flows into final tablets or coated forms used by millions of diabetes patients. Doctors worldwide have recognized Metformin as a first-line oral antidiabetic drug. Its primary role involves reducing hepatic glucose production and improving insulin sensitivity, which lays down a reliable foundation for effective disease management. On the floor, we routinely receive updates from partners about trends in formulation science—like modifications for extended-release tablets. Our role is to make sure every specification matches what modern dosage delivery requires, offering both standard and extended-release grades depending on customer demand.
Metformin interacts favorably with a wide selection of excipients and resists chemical degradation during tablet pressing, which helps build a robust supply chain in the competitive generic drug market. For this reason, leading generic manufacturers frequently rely on direct shipment from source chemical producers rather than on multi-tier distribution models. As a producer, our biggest responsibility—or challenge—is to uphold uninterrupted bulk supply so finished drug manufacturing doesn’t stall, especially during periods of heightened public health demand. This reliability supports government-approved stockpiling and public procurement, which has often put extra scrutiny on our lot tracking systems and logistics accuracy.
Unlike some bulk actives that face regular supply chain threats or price volatility, Metformin stands out for its stability, scalability, and lack of dependence on rare feedstocks. Our manufacturing method uses well-characterized reagents, minimizes hazardous intermediates, and produces minimal waste compared to more niche pharmaceutical raw materials, which helps us hold to tighter production costs and waste management standards.
Many active pharmaceutical ingredients require cold-chain shipping, oxygen-free storage, or extra stabilization steps. Metformin powder maintains physical and chemical integrity under normal storage conditions, simplifying logistics from our facilities to customer warehouses. This stability becomes especially practical during cross-continental shipments, as it mitigates the need for specialized handling and reduces risk of batch rejection due to shipping errors.
When compared to newer diabetes therapies—such as GLP-1 receptor agonists or SGLT2 inhibitors—Metformin stands out because bulk production costs significantly less, and raw materials are less subject to supply chain disruptions. Scaling production to meet increased demand rarely involves introducing exotic synthetic steps or dependence on hard-to-source starting materials. In our industry, this makes Metformin an anchor around which generics portfolios are built, giving both public and private sector drug makers confidence in multi-year procurement contracts.
From our production perspective, Metformin outperforms many other actives by allowing consistent batch yields regardless of order scale. It doesn’t require advanced containment for toxic intermediates, nor does it demand complex route changes as regulatory guidelines shift. This consistency and flexibility allow downstream partners to plan formulation timelines and minimize downtime, giving patients greater confidence in the availability of their daily medication.
Producing Metformin at high volumes brings challenges of scale, scrutiny, and documentation. Pharmacopeial changes, particularly concerning impurity limits, drive frequent process audits and product reformulations. For example, attention to N-nitrosamine contamination has become a top priority in recent years, following global regulatory alerts. We have invested in advanced analytical techniques, such as GC-MS and LC-MS/MS, to proactively screen for nitrosamines and adapt synthesis processes that produce no detectable nitrosamine impurities above stringent marketplace thresholds.
Annual revisions to analytical and validation methods keep quality assurance teams on their toes. Any hint of impurity or product deviation triggers a complete root-cause analysis and corrective action, which means delays for our own workflow but prevents potential recalls further down the drug supply chain. This process can stretch our capacity, as regulatory transparency requires meticulous electronic recordkeeping and traceable batch histories. Investing in upgraded laboratory instruments, frequent third-party audits, and continuous staff training became non-negotiable once Metformin joined the ranks of so-called high-volume, high-scrutiny actives.
Tightening oversight from authorities such as the US FDA, EMA, and local health agencies leads to dynamic specification management. Sometimes, a customer requests batch samples for pre-shipment re-testing or mandates additional certifications such as DMF (Drug Master File) registration, Kosher, Halal, or full compliance with new region-specific standards. Our manufacturing teams routinely coordinate with regulatory managers to ensure that releases match evolving requirements, often with little advance warning. Flexibility remains key—we batch test for a spectrum of possible contaminants, solvents, and impurities, even those not previously found in our processes. This agile approach builds lasting trust with both new and recurring partners.
Over the years, improvements in green chemistry and process intensification have transformed our approach to Metformin manufacturing. The industry has shifted away from older batch technologies to continuous and semi-continuous flow setups, resulting in lower solvent use and enhanced waste recycling. Solvent recovery now plays a central role in everyday production, and water stewardship—minimizing chemical oxygen demand—has driven us to overhaul both reactor design and purification trains.
Mitigating the environmental footprint of Metformin production also means investing in automation and real-time monitoring. Remote sensors and process control software track every parameter from reaction temperature to final powder drying, catching deviations before they create product quality risks. Our commitment to sustainability doesn’t just address regulatory pressure; energy savings and raw material yield improvements produce direct, measurable impacts to bottom-line costs. In the current landscape, even high-volume commodity actives like Metformin must demonstrate life-cycle responsibility to win government tenders or pass environmental and social governance (ESG) audits with pharmaceutical multinationals.
The push for greener practices has also led research teams to explore bio-based routes and alternative catalysts for key synthesis steps. While our primary process still draws on traditional synthetic chemistry, pilot projects are constantly underway to convert petrochemical routes to plant-based inputs wherever possible. Relentless improvements, both incremental and systemic, define how we see our obligations to customers and communities.
Bulk Metformin rarely enters the pharmaceutical value stream alone. Formulators routinely request co-delivery with analytical support, customized documentation, and supplementary testing for specific finished-drug requirements. We maintain a dedicated technical services group focused on supporting contract manufacturers through technology transfer, comparative dissolution profiling, or troubleshooting solubility in specific excipient matrices.
Our technical experts help address questions about compatibility, micronization, or packaging format. Many clients approach us during regulatory filings needing full documentation to show trace impurity management or evidence of compliance with photo-stability demands. In some cases, we handle tailored analytical testing—like stress testing in simulated gastric fluids—to directly support customer formulation work or post-approval changes.
Packaging requirements vary from market to market, but our focus on moisture-resistant, tamper-evident packaging ensures that Metformin crosses continents and climate zones without quality loss. Any change in industry standards triggers close review of packaging materials and seals. End users sometimes request secondary packaging reviews by third-party auditors, and our production planners must accommodate these parallel review cycles without delaying on-time shipment.
Documentation and transparency sit at the heart of our supply relationships. Each order ships with a full certificate of analysis and a cross reference to the originating batch and facility. Should a client or regulatory body require an audit of our manufacturing records, every step—from solvent ordering to final QC release—sits open for review, driving confidence in pharmaceutical supply chain stewardship. We view this transparency as both a market requirement and a professional obligation to those relying on regular, reliable access to Metformin tablets.
From our perspective as a primary source manufacturer, the market for Metformin demonstrates both remarkable resilience and periodic spikes in demand linked to global diabetes trends. During the COVID-19 pandemic, we witnessed extraordinary short-term bulk orders from major public health programs, forcing us to stretch capacity and reorganize cross-border logistics to maintain delivery schedules.
Supply chain security concerns and rising interest in domestic production have seen regional drug authorities tightening their review of import licenses. Some countries implement additional testing protocols or restrict procurement to API produced under specific local certifications. This reality prompts us to regularly invest in registration support, batch sampling, and bespoke documentation to meet local regulatory expectations across continents.
Differentiation between factory-produced, directly shipped Metformin and product handled via traders, intermediaries, or resellers has become more pronounced. Direct-from-manufacturer qualification processes sometimes include facility audits, quality system evaluations, and full disclosure of production protocols. Customers—especially those producing essential medicines for government procurement lists—won’t consider alternative sources without this direct visibility. The trust built through consistent direct supply relationships has become a prized asset for both our business and our partners’ long-term planning.
Manufacturing Metformin at scale requires collaboration with both raw material suppliers and end users. We work closely with primary input suppliers to secure consistent, traceable, and high-quality amine and chloro compounds, negotiating locked-in volumes and pre-qualifying new vendors every fiscal year. Fluctuations in global commodity chemical markets, such as those affecting acetonitrile or methanol supply, can ripple quickly through production costs, so forward purchase agreements and dual sourcing have become routine safeguards.
The transition to more automated, digitalized chemical production brings opportunities but also demands ongoing staff training and IT investment. Digital batch record systems and real-time environmental monitoring not only support regulatory compliance, but also give our management team vital feedback about process yields, downtime, and quality trends. Cybersecurity—in an age of more connected plants—forms an emerging area of risk and required investment, as even small-scale data breaches can threaten both intellectual property and regulatory standing.
Open dialogue with downstream customers has helped us anticipate regulatory changes and evolving market needs. Our commercial and technical teams routinely participate in multi-company working groups, industry consortia, and technical panels focused on topics like impurity control, environmental impact, and best practices for continuous manufacturing. This spirit of cooperation drives process evolution and keeps everyone honest when supply challenges force urgent solutions or quality deviations occur.
The pharmaceutical landscape will never stop changing, and Metformin remains both a legacy product and a modern production challenge. Research groups, both inside and outside our company, keep exploring novel synthesis routes, process intensification, and improved downstream formulation science. Ongoing projects target everything from increasing API purity beyond current pharmacopeia requirements to developing fully solvent-free synthesis steps that further cut environmental impact.
Finished drug formulators often share early R&D findings with our teams, looking for ways to combine Metformin with newer antidiabetic drugs in fixed-dose combinations. Each new approach demands support from the chemical manufacturing side, as slight changes in final form or dosage method can reverberate backward into particle size handling, impurity tracking, or packaging stability. Our on-the-ground manufacturing teams work in tandem with R&D, ensuring that process changes don’t introduce new sources of contamination or threaten batch reliability.
Nimble response to regulatory shifts remains a constant. Global guidelines for pharmaceutical traceability, serialization, and anti-counterfeiting measures now require manufacturers to adapt packaging and supply chain management. We implement serialization and authentication steps at the source, even before such mandates reach every market, because long-term brand reputation relies more on prevention than problem-solving after the fact.
Metformin’s history as an effective antidiabetic agent puts a daily sense of responsibility on every production manager and plant operator here. Meeting orders for thousands of kilograms destined for hospitals, government agencies, and local pharmacies translates into real-world impact for patients living with chronic disease. Each strategic investment—whether in better containment systems or more sensitive analytical tools—feeds directly into both quality and access.
Our job doesn’t end at consistently filling orders. We work to make sure our partners receive proactive support for regulatory filings, technical troubleshooting, and even crisis management when unexpected global events threaten to disrupt shipment lanes. These aren’t abstract ideals, but practical steps grounded in decades of hands-on production, audit response, and daily workflow monitoring.
Every day, trust in bulk Metformin depends not just on historical brand reputation, but on visible, documentable, and repeatable quality. Our teams wake up to changing laws, emerging scientific reports, and shifting public health priorities. Meeting these expectations sets the foundation for safe, affordable, and available treatment for millions who depend on Metformin as an irreplaceable piece of their healthcare routine.
